These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34937699)

  • 1. SARS-CoV-2 spreads through cell-to-cell transmission.
    Zeng C; Evans JP; King T; Zheng YM; Oltz EM; Whelan SPJ; Saif LJ; Peeples ME; Liu SL
    Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34937699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Spreads through Cell-to-Cell Transmission.
    Zeng C; Evans JP; King T; Zheng YM; Oltz EM; Whelan SPJ; Saif L; Peeples ME; Liu SL
    bioRxiv; 2021 Jun; ():. PubMed ID: 34100011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
    Hoffmann M; Arora P; Groß R; Seidel A; Hörnich BF; Hahn AS; Krüger N; Graichen L; Hofmann-Winkler H; Kempf A; Winkler MS; Schulz S; Jäck HM; Jahrsdörfer B; Schrezenmeier H; Müller M; Kleger A; Münch J; Pöhlmann S
    Cell; 2021 Apr; 184(9):2384-2393.e12. PubMed ID: 33794143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma.
    Wang L; Zhao J; Nguyen LNT; Adkins JL; Schank M; Khanal S; Nguyen LN; Dang X; Cao D; Thakuri BKC; Lu Z; Zhang J; Zhang Y; Wu XY; El Gazzar M; Ning S; Moorman JP; Yao ZQ
    Sci Rep; 2021 Mar; 11(1):5558. PubMed ID: 33692386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
    Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
    Viruses; 2021 May; 13(5):. PubMed ID: 34065987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.
    Hoffmann M; Zhang L; Krüger N; Graichen L; Kleine-Weber H; Hofmann-Winkler H; Kempf A; Nessler S; Riggert J; Winkler MS; Schulz S; Jäck HM; Pöhlmann S
    Cell Rep; 2021 Apr; 35(3):109017. PubMed ID: 33857422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
    Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC
    EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.
    Yue S; Li Z; Lin Y; Yang Y; Yuan M; Pan Z; Hu L; Gao L; Zhou J; Tang J; Wang Y; Tian Q; Hao Y; Wang J; Huang Q; Xu L; Zhu B; Liu P; Deng K; Wang L; Ye L; Chen X
    Front Immunol; 2021; 12():751584. PubMed ID: 34630430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
    Stelitano D; Weisberg SP; Goldklang MP; Zhu Y; Bovier FT; Kalantarov GF; Greco G; Decimo D; Franci G; Cennamo M; Portella G; Galdiero M; Mathieu C; Horvat B; Trakht IN; Moscona A; Whitt MA; Porotto M
    mSphere; 2021 Aug; 6(4):e0057121. PubMed ID: 34319126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
    Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
    J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.
    Yi Z; Ling Y; Zhang X; Chen J; Hu K; Wang Y; Song W; Ying T; Zhang R; Lu H; Yuan Z
    Emerg Microbes Infect; 2020 Dec; 9(1):1988-1996. PubMed ID: 32844713
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.